CoChat

Strong expression of ID1 protein is associated with decreased survival, increased expression of ephrin-A1/EPHA2, and reduced thrombospondin-1 in malignant melanoma

Open access
Straume, O, Akslen, L A · 2005 · British Journal of Cancer

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

The ID1 protein, an inhibitor of basic helix-loop-helix transcription factors, has been involved in multiple cellular processes including cell cycle regulation, apoptosis, and angiogenesis. To evaluate the importance of ID1 in malignant melanoma, tumour cell expression was examined by immunohistochemistry in 119 cases of nodular melanoma using tissue microarray technique, and related to multiple tumour markers including proliferation, p16 expression, angiogenesis and patient survival. Strong ID1 expression was significantly associated with increased tumour thickness, and significantly reduced survival. Also, increased ID1 was associated with loss of thrombospondin-1 (TSP-1) expression, a known inhibitor of angiogenesis, and increased intensity of ephrin-A1 and its receptor EPHA2. Presence of BRAF mutations was related to strong ID1 expression, but there was no relationship with p16 protein expression. Further, no significant correlation was found between ID1 and microvessel density. In conclusion, our study supports a significant role of the ID1 protein in melanoma progression and patient prognosis. The absence of correlation with p16 protein expression and angiogenesis suggests that other regulatory pathways and mechanisms might be influenced by ID1 in melanomas. An inverse relation between ID1 and TSP-1 expression support an important role of ID1 in the regulation of this complex multitarget protein.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6602792

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 (A) Immunohistochemical staining of ID1 protein in human malignant melanoma. Note the strong cytoplasmic expression in tumour cells (arrow). Scale bar 50 μm. (B) ID1 is strongly positive in perivascular cells (arrow), and some weaker staining is observed in the endothelial cells (arrowhead). (C) In this case, ETS-1 protein by immunohistochemistry is strongly positive in the cytoplasm and nuclei of tumour cells (arrow).
Figure 1 (A) Immunohistochemical staining of ID1 protein in human malignant melanoma. Note the strong cytoplasmic expression in tumour cells (arrow). Scale bar 50 μm. (B) ID1 is strongly positive in perivascular cells (arrow), and some weaker staining is observed in the endothelial cells (arrowhead). (C) In this case, ETS-1 protein by immunohistochemistry is strongly positive in the cytoplasm and nuclei of tumour cells (arrow).CC BY · PubMed Central
Figure 2 Survival curves according to the Kaplan–Meier method by ID1 expression in nodular melanomas. (A) Patient survival with death due to melanoma as end point. (B) Recurrence-free survival by ID1 expression.
Figure 2 Survival curves according to the Kaplan–Meier method by ID1 expression in nodular melanomas. (A) Patient survival with death due to melanoma as end point. (B) Recurrence-free survival by ID1 expression.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

Metadata

Authors
Straume, O., & Akslen, L. A.
Affiliations
Haukeland University Hospital (NO)
Corresponding author
Akslen, L A
Venue
British Journal of Cancer
Published
2005-09-27
Volume
93
Issue
8
Pages
933-938
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2032702028
Cited by
42
References
40
Citations by year
2024: 1 · 2021: 2 · 2020: 3 · 2018: 2 · 2017: 1 · 2015: 2 · 2014: 3 · 2013: 1 · 2012: 1
FWCI
1.51
Type
journal article
Language
en
Open access
Locations
  • British Journal of Cancer (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Helse Vest
  • Norges Forskningsråd
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Keywords
Id1, nodular melanoma, thrombospondin-1, ephrin-A1, EphA2, tumor thickness, patient survival, prognosis, BRAF mutation, p16, angiogenesis, microvessel density, tumor progression, bHLH transcription factors
MeSH terms
Cell Survival, Humans, Immunohistochemistry, Melanoma, Neovascularization, Pathologic, Prognosis, Skin Neoplasms, Biomarkers, Tumor, Up-Regulation, Disease-Free Survival, Thrombospondin 1, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Ephrin-A1, Ephrin-A2, Inhibitor of Differentiation Protein 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.